Relafen 750, pharmacologically known as naproxen, showcases a fascinating case study within the molecular pharmacy domain . Its therapeutic effect copyrights on inhibiting cyclooxygenase catalysts , specifically COX-1 and COX-2, thereby lessening the synthesis of prostaglandins, which are key mediators of inflammation and heat. This targeted inhibi